TOP-5 studies on disease treatment from 28.06.2026 - 05.07.2026
Low glycemic index diets and their impact on glycemic and lipid control in various populations: a systematic review and meta-analysis; How dietary interventions affect oral health; Neoadjuvant tislelizumab (anti-PD-1 antibody) combined with chemotherapy in patients with progressive epithelial ovarian cancer: the NAIVE study; Dual targeting of organelles by nanomaterials: therapeutic effects and toxicological consequences driven by physicochemical properties; Dietary polyphenols as natural modulators of the NF-κB signaling pathway in inflammatory non-communicable diseases: a focus on cancer.
5. Low glycemic index diets and their impact on glycemic and lipid control in various populations: a systematic review and meta-analysis.
About the work.
The aim of the study was to assess the impact of low glycemic index diets on glycemic and lipid profiles in various populations. The study included a comparison of the results of low glycemic index diets with control diets.
Results.
Low glycemic index diets significantly reduced fasting blood glucose (-0.19 mmol/L, p = 0.04), glycated hemoglobin (-0.22%, p < 0.01), and LDL cholesterol levels (-0.15 mmol/L, p < 0.01). Low glycemic index diets also showed a trend towards increased HDL cholesterol levels and reduced fasting insulin, HOMA-IR, triglycerides, and total cholesterol.
4. How dietary interventions affect oral health: a systematic review.
About the work.
The aim of the study was to evaluate the impact of dietary interventions, such as fasting and caloric restriction, on oral health. The systematic review analyzed data on various diets and their effects on oral diseases.
Results.
Caloric restriction and intermittent fasting were generally associated with improved gum inflammation and metabolic parameters, with no significant changes in the composition of the oral microbiota. Alternate-day fasting showed a positive effect on salivary gland function and inflammatory responses in preclinical models.
3. Neoadjuvant tislelizumab (anti-PD-1 antibody) combined with chemotherapy in patients with progressive epithelial ovarian cancer: the NAIVE study.
About the work.
The study aimed to evaluate the effectiveness of neoadjuvant chemotherapy with tislelizumab compared to standard chemotherapy in patients with advanced epithelial ovarian cancer. The study included patients with stage IIIC-IV cancer according to FIGO classification.
Results.
NACI demonstrated numerically longer progression-free survival (27.2 vs. 21.8 months) and higher 1-year (92.3% vs. 83.3%) and 2-year (62.3% vs. 31.8%) progression-free survival rates. Better tumor responses were also observed, including a higher overall response rate (69.2% vs. 58.3%) and more R0 resections.
2. Dual targeting of organelles by nanomaterials: therapeutic effects and toxicological consequences driven by physicochemical properties.
About the work.
This review discusses the influence of the physicochemical properties of nanomaterials on their targeting to organelles and the associated therapeutic and toxicological effects. The mechanisms of interaction of nanomaterials with various organelles and factors affecting the effectiveness of their targeted action are discussed.
Results.
The available abstract does not provide detailed results.